62 results about "Lactobacillus johnsonii" patented technology

The invention relates to application of lactobacillus helveticus HH-LPH17 in preparation of medicine for assisting in relieving inflammatory bowel diseases and relates to the technical field of probiotic compositions.The probiotic composition for treating the inflammatory bowel diseases comprises, by weight, 10 parts to 80 parts of lactobacillus johnsonii LBJ 456, 10 parts to 60 parts of lactobacillus helveticus HH-LPH17, 10 parts to 60 parts of lactobacillus acidophilus HH-LA26 and 10 parts to 60 parts of bifidobacterium longum HH-BL18. The composition comprises the following components in parts by weight: 10-60 parts of bifidobacterium bifidum HH-BB27 and 10-60 parts of bifidobacterium longum subspecies infantis HH-BI27. According to the probiotic composition for treating the inflammatory bowel disease, probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating the inflammatory bowel disease is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of the inflammatory bowel disease.

An Akk11 strain-containing probiotic agent capable of relieving hyperuricemia, and the use thereof. Strains in the probiotic agent include an Akkermansia muciniphila Akk11 strain and a Lactobacillus johnsonii LJ09 strain. It is found in the present application that the two strains possess a potential interaction and can cooperate with each other, thereby synergizing the effect of relieving hyperuricemia, which is specifically manifested in: being capable of remarkably regulating uric acid metabolism and improving renal clearance functions; being capable of effectively inhibiting the activity of a key enzyme for uric acid synthesis so as to reduce the production of uric acid, and being capable of remarkably relieving renal damage and renal dysfunctions associated with high levels of uric acid.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

This invention proposes a molecular marker for *Lactobacillus japonicus*, which was deposited on February 7, 2023, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 26505. The molecular marker comprises a nucleotide sequence selected from one of the following: (1) the nucleotide sequence shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99%, or higher homology to the nucleotide sequence shown in SEQ ID NO: 24; or (3) a nucleotide sequence having one or more nucleotide substitutions, deletions, or insertions in the nucleotide sequence shown in SEQ ID NO: 24. Using the molecular marker of this invention, not only can the target *Lactobacillus japonicus* be screened quickly and easily, but it can also highly specifically identify the target *Lactobacillus japonicus*, eliminating interference from other strains.

The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and / or improving athletic ability.

The method includes the steps of providing a plant protein substrate and fermenting the plant protein substrate with a starter culture containing *Lactobacillus johnsonii*. The invention also relates to plant-based products from such fermentation and *Lactobacillus johnsonii* strains suitable for use in the invention. The invention further relates to peptides that impart and / or enhance rich flavors, methods for preparing such peptides, compositions containing such peptides, and the use of such peptides as flavoring agents.

The present invention relates to a strain of Lactobacillus johnsonii N5 and its application in preventing and treating enteritis and diarrhea. Lactobacillus johnsonii N5), was deposited in the China Center for Type Culture Collection on February 10, 2023, with the deposit number CCTCC NO: M2023104. The Lactobacillus johnsonii N5 was isolated from the fecal microorganisms of piglets resistant to heat stress-induced diarrhea. This Lactobacillus johnsonii N5 has the effect of alleviating enteritis and diarrhea, which is specifically reflected in: significantly enhancing the expression of intestinal epithelial tight junction proteins and cytoprotective heat shock protein 70, improving the immune balance of animal intestinal T cells, enhancing immune tolerance, and reducing the degree of intestinal inflammation and the occurrence of diarrheal diseases in animals. Therefore, Lactobacillus johnsonii N5 has a significant effect in preventing and treating diarrhea and related intestinal inflammatory diseases.

The application discloses a lactobacillus johnsonii OD-5 and application and products thereof, and belongs to the technical field of microorganisms. A technical problem to be solved by the application is to provide a lactobacillus johnsonii capable of treating kidney stones. A technical solution is a lactobacillus johnsonii OD-5 with a preservation number of CGMCC No. 38426. The lactobacillus johnsonii can reduce urine oxalic acid and regulate urine calcium, effectively correct abnormal urine biochemical conditions promoting stone formation, reduce related kidney function damage, and inhibit formation and deposition of calcium oxalate crystals in the kidney at a histopathological level, thereby significantly reducing the stone incidence. The application provides a solid theoretical basis for development of products taking the lactobacillus johnsonii OD-5 as a core component and used for preventing kidney stones and improving stone kidney damage.

The invention provides a preparation method of anti-inflammatory soothing and repairing microspheres based on Trichoderma reesei-Lactobacillus johnsonii two-stage fermentation. According to the preparation method, Trichoderma reesei fermentation products, Lactobacillus johnsonii metabolites, specific plant active ingredients and mussel mucoprotein are included. According to the invention, the mussel mucoprotein-trichoderma reesei-lactobacillus johnsonii ternary synergistic anti-inflammatory antibacterial system microspheres are innovatively constructed, the targeted delivery efficiency of active ingredients is remarkably improved through the adhesion characteristic of mussel mucoprotein, and the technical bottlenecks of poor permeability and short action time of a traditional anti-inflammatory preparation are solved. A multi-strain synergistic fermentation process is adopted, beta-glucan secreted by trichoderma reesei and short-chain fatty acid generated by lactobacillus johnsonii generate a synergistic anti-inflammatory effect, and meanwhile, an enzymolysis technology is combined to realize efficient conversion of plant active ingredients, so that the inhibition effect on key inflammatory factors such as TNF-alpha and IL-6 is remarkably enhanced. According to the system, inflammatory pathways such as NF-kappa B and the like are regulated and controlled through multiple targets, the inflammatory reaction is reduced while the growth of pathogenic bacteria is inhibited, a remarkable broad-spectrum antibacterial and anti-inflammatory synergistic effect is shown, and an innovative solution is provided for developing an efficient and safe anti-inflammatory antibacterial preparation.

The present application relates to lactic acid bacteria with blood sugar lowering function and application thereof, and particularly provides a group of lactic acid bacteria with high safety, which can play an important role in regulating intestinal microecological balance of human body and has blood sugar lowering effect.The lactic acid bacteria is named as Lactobacillus johnsonii 4437-4AT, the strain number is 4437-4AT, and was preserved in Guangdong Microbial Culture Collection Center on January 20, 2026, the preservation address is: No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100 Courtyard, the preservation number is: GDMCC NO: 67710.

The invention discloses a broiler feed additive containing chlorella and application of the broiler feed additive. The additive contains chlorella; the feed also contains one or more of lactobacillus johnsonii, enterococcus faecalis, saccharomyces cerevisiae and bacillus amyloliquefaciens. By adding the additive disclosed by the invention into daily ration, the intestinal tissue form can be improved by regulating antioxidant and immune functions, so that the growth performance of the broiler chicken can be remarkably improved. In the additive, lactobacillus johnsonii BS15 and enterococcus faecalis YP-2 are combined for use, and saccharomyces cerevisiae WHY-7 and bacillus amyloliquefaciens TL are combined for use, so that the average weight of the broiler chicken is increased, the spleen index after LPS stimulation is reduced, and synergistic interaction is achieved.

The invention discloses a lactic acid bacteria composition, lactic acid bacteria fermentation liquor, a lactic acid bacteria agent, fermented milk and a preparation method and application thereof, and belongs to the technical field of microorganisms. The lactobacillus composition disclosed by the invention is prepared from lactobacillus johnsonii S2L, lactobacillus reuteri S5L and lactobacillus mucous membrane mucus S16L; the preservation number of the lactobacillus johnsonii S2L is GDMCC No: 66569; the preservation number of the lactobacillus reuteri S5L is GDMCC No: 66558; the preservation number of the lactobacillus mucous membrane S16L is GDMCC No: 66559. The strains in the lactic acid bacteria composition have excellent probiotic characteristics, do not have virulence factors, are fermented in the milk replacer, are short in fermentation time, can improve the protein hydrolysis degree of the milk replacer, reduce the incidence rate of lamb diarrhea and optimize the intestinal microflora, and have positive effects on improving the feed intake of lambs.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus johnsonii with a function of resisting multiple drug-resistant bacterium biological membranes and anti-inflammatory activity and application of the lactobacillus johnsonii. The lactobacillus johnsonii A25041 provided by the invention has strong inhibition and anti-biofilm activity on multi-drug-resistant gram-negative bacteria (including escherichia coli, pseudomonas aeruginosa and acinetobacter baumannii) and methicillin-resistant staphylococcus aureus, and the lactobacillus johnsonii A25041 has good acid-base tolerance and gastrointestinal fluid tolerance, so that the lactobacillus johnsonii A25041 can be used for preparing medicines for preventing and treating various diseases. The composition shows excellent anti-inflammatory activity and oxidation resistance, does not have hemolysis capacity, is good in safety, has natural drug resistance to gentamicin, tetracycline, ciprofloxacin, lincomycin and compound sulfamethoxazole, can be used together with antibiotics at the same time or in sequence, maintains intestinal microecological balance and relieves antibiotic burden while exerting the sterilization effect of the antibiotics, and has a good application prospect. The method can be widely applied to functional food development, and has important application value in the field of biological medicine and daily chemical products.

The present application relates to a lactobacillus johnsonii producing a novel class III bacteriocin, an engineered bacterium and application thereof, and belongs to the technical field of microorganisms. Lactobacillus johnsonii The JLJ071 strain of the lactobacillus johnsonii is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.34541. The bacteriocin amino acid sequence is shown in Seq ID No.1. The expressed novel class III bacteriocin has good bactericidal activity on listeria monocytogenes and salmonella pullorum, and has good characteristics such as acid resistance, high temperature resistance and protease resistance, and has a good application prospect in feed additives.

This invention relates to a lactobacillus composition for alleviating atopic dermatitis. This lactobacillus composition comprises at least one of *Lactobacillus johnsonii* strain GKJ2 and *Lactobacillus plantarum* strain GKK1. When administered to subjects suffering from atopic dermatitis for a continuous period, it can regulate Th1, Th2, Treg, and Th17 cellular immunity, alter the intestinal flora, and increase the concentration of short-chain fatty acids in the intestine, thereby alleviating atopic dermatitis. Therefore, this lactobacillus composition can be used as an active ingredient in the preparation of various compositions for alleviating atopic dermatitis.

The present disclosure provides use of a probiotic composition comprising active ingredients including Lactobacillus johnsonii, Lactobacillus gasseri, Lactobacillus crispatus, and Lactobacillus jensenii in the preparation of a microbial formulation, wherein the microbial formulation is used for: improving the therapeutic effect of an additional drug for treating bacterial vaginosis in the treatment of bacterial vaginosis; improving the prognosis of bacterial vaginosis treated with an additional drug for treating bacterial vaginosis; treating, preventing, mitigating, and / or controlling the recurrence of bacterial vaginosis in a subject; treating, preventing, mitigating, and / or controlling atrophic vaginitis in a subject; improving the Nugent score of a subject; or ameliorating vaginal dryness in a subject.

The invention discloses application of lactobacillus johnsonii or extracellular vesicles derived from the lactobacillus johnsonii in preparation of medicines for treating and / or preventing adult degenerative scoliosis. Experiments prove that the extracellular vesicles derived from lactobacillus johnsonii can promote synthesis of extracellular matrix (ECM) of nucleus pulposus cells derived from adult degenerative scoliosis (ADS), inhibit ECM degradation and effectively reverse nucleus pulposus ECM metabolism abnormality in the ADS progress process, and prompt that the extracellular vesicles can improve the ADS disease progress by regulating nucleus pulposus cell ECM metabolism.

The invention discloses a composition helpful for controlling in-vivo fat and application thereof, and relates to the technical field of biology. The hesperidin composition is prepared from hesperidin and lactobacillus johnsonii (Lactobacillus johnsonii), and the hesperidin composition is prepared from the hesperidin and the lactobacillus johnsonii. Research finds that the composition can achieve synergistic up-regulation of gene and protein expression of adipose tissue PGC1alpha and UCP1 and increase the body surface temperature; the composition can also significantly improve the bioavailability of hesperidin and improve the concentration of hesperetin and other metabolites in serum; the composition can also optimize the intestinal microecology, improve the intestinal flora structure, increase the lactobacillus colonization rate, enrich the abundance of beneficial bacteria and promote the generation of short-chain fatty acids; the composition can also significantly improve lipid metabolism disorder of an organism, reduce fat accumulation, regulate adiponectin and leptin levels, control fat in the body and realize effective weight loss management.

The invention relates to the field of biological medicine, and discloses a composition targeting a lactobacillus johnsonii-tryptophan metabolic axis and application of the composition. The composition comprises a traditional Chinese medicine extract and lactobacillus johnsonii, the traditional Chinese medicine extract is prepared from radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root. Traditional Chinese medicine extracts of radix bupleuri, radix paeoniae alba, fructus aurantii immaturus and honey-fried licorice root are compounded with lactobacillus johnsonii according to a specific proportion, tryptophan is promoted to be converted into 5-hydroxytryptamine, kynurenine is inhibited from being generated, depression-like behaviors are effectively relieved, the traditional Chinese medicine composition can cooperate with anticancer drugs to remarkably inhibit cancer cell growth, meanwhile, the intestinal barrier function can be improved, the intestinal immunity can be improved, and the curative effect is good. The invention provides a high-safety synergistic treatment scheme with triple effects of tumor inhibition, depression resistance and intestinal tract improvement for patients with liver cancer and depression.

The invention discloses a method for regulating and controlling growth and metabolism of probiotics through low-intensity pulsed ultrasound and application of the method. The method comprises the steps that S1, a standardized co-culture system is obtained; s2, collecting co-culture flora density data and co-culture metabolite concentration data; s3, generating an optimal irradiation parameter record; s4, obtaining a steady-state co-culture product; s5, preparing a probiotic preparation containing lactobacillus johnsonii according to co-culture evaluation data, namely lactobacillus johnsonii which is subjected to low-intensity pulse ultrasonic irradiation and is suitable for growth and active in metabolism; s6, giving a probiotic preparation to the animal model, and meanwhile, applying low-intensity pulse ultrasonic irradiation corresponding to the optimal irradiation parameter record to the body surface positioning area of the animal intestinal tract to form an in-vivo joint regulation process; and S7, generating in-vivo regulation and control effect evaluation data. The low-intensity pulse ultrasonic technology is used, and side effects possibly caused by chemical drugs, gene modification and the like are avoided.

The invention belongs to the technical field of microbial fermentation engineering, and particularly relates to a method for increasing the yield of extracellular vesicles of lactobacillus bacteria. The method comprises the following steps: adding galactooligosaccharide into a lactobacillus selective culture medium, inoculating lactobacillus bacteria, and culturing; separating and purifying the cultured bacterial liquid to obtain extracellular vesicles; wherein the concentration of the galactooligosaccharide in the lactobacillus selective culture medium is 30 g / L-50 g / L. According to the invention, galactooligosaccharide is added in the culture of lactobacillus johnsonii, so that the production of extracellular vesicles of lactobacillus johnsonii can be effectively improved. The method can be used for industrial mass production of the lactobacillus johnsonii extracellular vesicles, and has important value in the field of production of the lactobacillus johnsonii extracellular vesicles.

The invention provides application of lactobacillus johnsonii YH1136 inactivated thalli in preparation of products for relieving depression, anxiety and sleep disorders, and relates to the technical field of microorganisms. The inactivated thallus is obtained by carrying out heat treatment on live thallus of lactobacillus johnsonii YH1136 with the preservation number of CCTCC NO: M 20221116 at 60 to 68 DEG C for 30 to 90 minutes. Animal experiments show that the inactivated thallus can significantly improve depression-like behaviors, anxiety-like behaviors and sleep disorders of CUMS model mice, and the effect of the inactivated thallus is equivalent to that of viable bacteria and positive drug fluoxetine, and is significantly superior to that of 100 DEG C traditional high-temperature inactivated thallus. The action mechanism is related to inhibition of HPA hyperfunction and up-regulation of hippocampal brain-derived neurotrophic factors and prefrontal cortex 5-hydroxytryptamine levels. The inactivated thallus provided by the invention is high in stability, good in safety and suitable for developing related drugs.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.

This invention discloses the application of *Lactobacillus johnsonii* cell-free supernatant in inhibiting *Salmonella* biofilms, belonging to the field of microbial technology. This invention provides a novel use for *Lactobacillus johnsonii* BNCC186110 cell-free supernatant, which can inhibit the formation of *Salmonella typhimurium* SL1344 and 14028 biofilms, disrupt *Salmonella typhimurium* SL1344 and 14028 biofilms, thereby reducing the colonization of *Salmonella typhimurium* SL1344 and 14028.

The invention discloses human-derived lactobacillus johnsonii HA1108 and application thereof in preparation of biological agents and / or medicines for treating or relieving Parkinson's disease, and belongs to the technical field of biological medicines. The invention provides a strain of lactobacillus johnsonii, which is classified and named as Lactobacillus johnsonii, and the preservation number of the lactobacillus johnsonii is CGMCC (China General Microbiological Culture Collection Center) No.35865. Based on'flora-intestine-brain axis', the lactobacillus johnsonii HA1108 can improve dyskinesia in Parkinson's disease, relieve deletion of dopaminergic neurons of nigra in the brain, increase protein expression of tyrosine hydroxylase at the nigra part in the brain, and improve the immunity of the Parkinson's disease. The microbial inoculum prepared from the lactobacillus johnsonii HA1108 does not affect the body weight after being eaten for a long time, and a new choice is provided for patients with Parkinson's disease. The screened lactobacillus johnsonii HA1108 has important significance in preparation of biological agents or medicines for treating or relieving Parkinson's disease, improving dyskinesia and improving tyrosine hydroxylase expression, has safety and application value, and is wide in market prospect.

The invention belongs to the technical field of microorganisms, and particularly relates to a preparation method and application of a lactobacillus johnsonii ZJUIDS09 metagen capable of improving human immunity. The invention discloses a preparation method of a lactobacillus johnsonii ZJUIDS09 metagen capable of improving immunity. The lactobacillus johnsonii ZJUIDS09 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.22608 is used for preparing the lactobacillus johnsonii ZJUIDS09 metagen. The invention also provides an application of the lactobacillus johnsonii ZJUIDS09 metagen prepared by the method in preparation of a product for improving immunity at the same time.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The application discloses a cough relieving and asthma relieving composition and belongs to the field of traditional Chinese medicines. The cough relieving and asthma relieving composition is made of traditional Chinese medicine fermentation granules, bitter apricot kernels, perilla leaves and radix peucedani. The traditional Chinese medicine fermentation granules are made of pericarpium citri reticulatae, platycodon grandiflorum and glycyrrhiza uralensis as raw materials. Cellulase is used to enzymatically hydrolyze the raw materials to obtain an enzymatic hydrolysis liquid. Then, lactobacillus plantarum, lactobacillus johnsonii and rhodotorula mucilaginosa are used to mix ferment the enzymatic hydrolysis liquid to obtain a fermentation liquid. The fermentation liquid is sterilized, filtered, dried and granulated to obtain the traditional Chinese medicine fermentation granules. The traditional Chinese medicine fermentation granules, the bitter apricot kernels, the perilla leaves and the radix peucedani are used in combination and have a synergistic effect, so that an excellent cough relieving and asthma relieving effect is achieved.

The invention discloses lactobacillus johnsonii with bacteriostatic activity and high digestive tract tolerance and application of the lactobacillus johnsonii, the lactobacillus johnsonii is a new strain HL-RH01, can inhibit growth of helicobacter pylori and can inhibit adhesion of the helicobacter pylori to human gastric mucosa epithelial cells, and meanwhile, the lactobacillus johnsonii has good digestive tract tolerance. Active freeze-dried bacterial powder prepared from the strain can effectively remove helicobacter pylori colonized in a model animal body, and the removal effect is obviously better than that of antibiotic (clarithromycin). The lactobacillus johnsonii with a remarkable bacteriostatic effect is used for treatment or adjuvant treatment of helicobacter pylori infection, so that the clinical problems of low patient compliance and non-ideal eradication effect caused by use of a large dose of antibiotics can be relieved to a certain extent; a wider selection space is provided for the probiotics as a new way for treating helicobacter pylori infection.